Compare APGE & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APGE | ICUI |
|---|---|---|
| Founded | 2022 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2023 | 1992 |
| Metric | APGE | ICUI |
|---|---|---|
| Price | $68.17 | $144.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | $103.33 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 1.1M | 257.4K |
| Earning Date | 03-02-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.20 | $107.00 |
| 52 Week High | $84.56 | $165.17 |
| Indicator | APGE | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 41.93 |
| Support Level | $60.35 | $140.66 |
| Resistance Level | $66.18 | $155.90 |
| Average True Range (ATR) | 4.02 | 5.06 |
| MACD | 0.20 | -1.12 |
| Stochastic Oscillator | 77.58 | 23.56 |
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.